These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15709881)

  • 21. A new strategy of drug treatment in NSAID--unresponsive ankylosing spondylitis.
    Chogle AR; Mishra H; Chakravarty A
    J Assoc Physicians India; 2007 May; 55():380; author reply 380-1. PubMed ID: 17844703
    [No Abstract]   [Full Text] [Related]  

  • 22. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
    Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
    Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.
    Escalas C; Trijau S; Dougados M
    Rheumatology (Oxford); 2010 Jul; 49(7):1317-25. PubMed ID: 20360041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of spondyloarthropathy: new pharmacological treatment options.
    Lee RZ; Veale DJ
    Drugs; 2002; 62(16):2349-59. PubMed ID: 12396227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?
    Dayer JM; Krane SM
    N Engl J Med; 2002 May; 346(18):1399-400. PubMed ID: 11986415
    [No Abstract]   [Full Text] [Related]  

  • 26. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.
    Toussirot E
    Expert Opin Pharmacother; 2017 Feb; 18(3):275-282. PubMed ID: 28099816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TNF therapy for spondyloarthropathy: can we marshal the argument?
    Dawes PT; Packham JC; Mucklow JC
    Rheumatology (Oxford); 2004 Sep; 43(9):1069-71. PubMed ID: 15280568
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.
    Braun J; van der Heijde D
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1097-109. PubMed ID: 12831346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial.
    Proft F; Muche B; Listing J; Rios-Rodriguez V; Sieper J; Poddubnyy D
    BMJ Open; 2017 Jun; 7(6):e014591. PubMed ID: 28601821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current use of biologicals for the treatment of spondyloarthropathies.
    Keyser FD; Mielants H; Veys EM
    Expert Opin Pharmacother; 2001 Jan; 2(1):85-93. PubMed ID: 11336571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment of ankylosing spondylitis.
    Scalapino KJ; Davis JC
    Clin Exp Med; 2003 Feb; 2(4):159-65. PubMed ID: 12624705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials.
    Toussirot E; Vauchy C; Binda D; Michel F
    Drug Des Devel Ther; 2016; 10():2087-94. PubMed ID: 27445459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-TNF-alpha therapy in ankylosing spondylitis.
    De Keyser F; Van den Bosch F; Mielants H
    Cytokine; 2006 Mar; 33(5):294-8. PubMed ID: 16516484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis: comment on the article by Maksymowych et al.
    Singh R; Menon Y; Cuchacovich R; Espinoza LR
    Arthritis Rheum; 2003 Feb; 48(2):583-4; author reply 584. PubMed ID: 12571878
    [No Abstract]   [Full Text] [Related]  

  • 35. Bisphosphonates vs infliximab in ankylosing spondylitis treatment.
    Viapiana O; Gatti D; Idolazzi L; Fracassi E; Adami S; Troplini S; Povino MR; Rossini M
    Rheumatology (Oxford); 2014 Jan; 53(1):90-4. PubMed ID: 24067888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison.
    Wang Y; Wang H; Jiang J; Zhao D; Liu Y
    Cell Physiol Biochem; 2016; 39(5):1679-1694. PubMed ID: 27643888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ankylosing spondylitis.
    Braun J; Sieper J
    Lancet; 2007 Apr; 369(9570):1379-1390. PubMed ID: 17448825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
    Kristensen LE; Jakobsen AK; Askling J; Nilsson F; Jacobsson LT
    Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1137-49. PubMed ID: 25623277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient efficacy of pulse pamidronate treatment in active spondylarthropathies: an open study of 35 cases.
    Toussirot E; Le Huédé G; Lohse A; Cédoz JP; Wendling D
    Clin Exp Rheumatol; 2006; 24(3):348. PubMed ID: 16870109
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
    Kiltz U; Heldmann F; Baraliakos X; Braun J
    Curr Opin Rheumatol; 2012 May; 24(3):252-60. PubMed ID: 22450391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.